复宏汉霖(02696.HK) 公布,与卫采Eisai(4523.JP)订立许可协议。公司同意向Eisai授出一项许可,供其于日本及领域内开发、生产和商业化汉斯状(斯鲁利单抗注射液)。Eisai将向公司支付首付款7,500万美元,监管里程碑款项合计至多8,001万美元,商业销售里程碑款项合计至多约2.3亿美元,以及产品于区域内年度净销售额的两位数百分比的特许权使用费。汉斯状为公司自主开发的创新型抗...
Source Link复宏汉霖(02696.HK) 公布,与卫采Eisai(4523.JP)订立许可协议。公司同意向Eisai授出一项许可,供其于日本及领域内开发、生产和商业化汉斯状(斯鲁利单抗注射液)。Eisai将向公司支付首付款7,500万美元,监管里程碑款项合计至多8,001万美元,商业销售里程碑款项合计至多约2.3亿美元,以及产品于区域内年度净销售额的两位数百分比的特许权使用费。汉斯状为公司自主开发的创新型抗...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.